Compare Stocks → Your Money is Not Safe (From American Alternative) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:EMCNASDAQ:IMPLNASDAQ:KLDONASDAQ:RPHM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$25.07+0.2%$0.00$22.99▼$29.13N/AN/A13.90 million shs26,330 shsIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shsKLDOKaleido Biosciences$0.00$0.00▼$0.03$4K-0.064,281 shs1,250 shsRPHMReneo Pharmaceuticals$1.69-2.9%$1.66$0.98▼$10.98$58.15M0.2489,792 shs181,894 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC+0.20%-1.78%-3.39%+1.42%-13.70%IMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%-97.80%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%RPHMReneo Pharmaceuticals-2.87%+1.81%+1.81%+0.60%-83.90%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMCEMC0.5382 of 5 stars0.04.01.70.00.01.70.7IMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ARPHMReneo Pharmaceuticals0.8886 of 5 stars2.90.00.00.00.62.51.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMCEMCN/AN/AN/AN/AIMPLImpel PharmaceuticalsN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/ARPHMReneo Pharmaceuticals1.88Reduce$18.14973.22% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMCEMCN/AN/AN/AN/AN/AN/AIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00KLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNRPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMCEMCN/A$2.0512.23∞N/AN/AN/AN/AN/AIMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ARPHMReneo Pharmaceuticals-$77.39M-$2.52N/AN/AN/AN/A-73.14%-63.85%5/9/2024 (Estimated)Latest RPHM, KLDO, NCYT, IMPL, and EMC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023RPHMReneo Pharmaceuticals-$0.55-$0.70-$0.15-$0.70N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMCEMC$0.461.83%N/A22.44%N/AIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMCEMCN/AN/AN/AIMPLImpel PharmaceuticalsN/A0.190.13KLDOKaleido BiosciencesN/AN/AN/ARPHMReneo PharmaceuticalsN/A5.875.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMCEMC79.86%IMPLImpel Pharmaceuticals73.88%KLDOKaleido Biosciences81.56%RPHMReneo Pharmaceuticals90.98%Insider OwnershipCompanyInsider OwnershipEMCEMC0.40%IMPLImpel Pharmaceuticals6.20%KLDOKaleido Biosciences9.00%RPHMReneo Pharmaceuticals17.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMCEMCN/AN/AN/ANot OptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionableRPHMReneo Pharmaceuticals833.42 million27.44 millionOptionableRPHM, KLDO, NCYT, IMPL, and EMC HeadlinesSourceHeadlineReneo Pharmaceuticals Inc.thestreet.com - April 14 at 1:20 PMReneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 0.6%marketbeat.com - April 3 at 2:35 AMSell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Targetmarkets.businessinsider.com - March 31 at 7:14 PMReneo Pharmaceuticals: Q4 Earnings Insightsbenzinga.com - March 28 at 4:09 PMRPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023investorplace.com - March 28 at 2:01 PMReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Updatefinanznachrichten.de - March 28 at 10:52 AMReneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Updateglobenewswire.com - March 28 at 7:35 AMReneo Pharmaceuticals, Inc. (RPHM)uk.finance.yahoo.com - February 14 at 12:17 AMReneo Pharmaceuticals, Inc. (RPHM)uk.finance.yahoo.com - February 14 at 12:17 AMReneo Pharmaceuticals Inc (RPHM)investing.com - January 30 at 1:28 AMReneo Shares Dive 83% After Drug Fails Trialocbj.com - January 8 at 8:25 PMSharp increase in RPHM’s short interest leads to surge in days-to-cover ratioknoxdaily.com - January 4 at 12:32 PMWhy Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionmsn.com - December 27 at 3:51 PMAnalysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)markets.businessinsider.com - December 19 at 5:49 PMHold Rating on Reneo Pharmaceuticals Following Lead Drug Trial Failure and Strategic Uncertaintymarkets.businessinsider.com - December 16 at 9:33 AMJefferies Downgrades Reneo Pharmaceuticals (RPHM)msn.com - December 16 at 9:33 AMReneo in trouble after trial failure scotches mavodelpar hopesthepharmaletter.com - December 15 at 12:31 PMReneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Studyfinance.yahoo.com - December 15 at 12:31 PMReneo Pharmaceuticals just downgraded at BofA, here's whyrealmoney.thestreet.com - December 15 at 7:30 AM5 Analysts Have This to Say About Reneo Pharmaceuticalsmarkets.businessinsider.com - December 15 at 7:30 AMReneo Pharmaceuticals just downgraded at Piper Sandler, here's whyrealmoney.thestreet.com - December 15 at 1:35 AMReneo Pharmaceuticals just downgraded at Leerink, here's whyrealmoney.thestreet.com - December 15 at 1:35 AMRare disease company Reneo stops all developmentbioworld.com - December 14 at 8:35 PMReneo Pharma Hits All-Time Low on Job Cuts, Halted Mavodelpar Developmentmarketwatch.com - December 14 at 3:34 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioPVH Stock Gets 25% Discount: Is Now the Time to Buy?April 2, 2024 11:25 AMView PVH Stock Gets 25% Discount: Is Now the Time to Buy?Delta Airline’s Put Option Activity Isn’t Bad NewsMarch 28, 2024 8:55 AMView Delta Airline’s Put Option Activity Isn’t Bad NewsIt’s Time to Buy Into the Super Micro Computer Stock ImplosionApril 22, 2024 12:33 PMView It’s Time to Buy Into the Super Micro Computer Stock Implosion3 High Short Interest Stocks Ready to Squeeze April 9, 2024 7:04 AMView 3 High Short Interest Stocks Ready to Squeeze All Headlines Company DescriptionsEMCNYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Impel PharmaceuticalsNASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Reneo PharmaceuticalsNASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.